RA Capital Management’s Day One Biopharmaceuticals DAWN Stock Holding History

RA Capital Management’s Portfolio DAWN Stock Details DAWN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,755,577	Closed	-$45.6M	–	69
2025 Q1	$45.6M	Hold	5,755,577	–	–	0.76%	25
2024 Q4	$72.9M	Sell	5,755,577 -2,116,144	-27%	-$29.4M	0.97%	24
2024 Q3	$110M	Hold	7,871,721	–	–	1.26%	23
2024 Q2	$108M	Buy	7,871,721 +61,869	+0.8%	+$905K	1.43%	20
2024 Q1	$129M	Hold	7,809,852	–	–	1.64%	19
2023 Q4	$114M	Hold	7,809,852	–	–	1.78%	13
2023 Q3	$95.8M	Hold	7,809,852	–	–	1.89%	14
2023 Q2	$93.2M	Buy	7,809,852 +769,230	+11%	+$10M	1.76%	17
2023 Q1	$94.1M	Hold	7,040,622	–	–	2.13%	16
2022 Q4	$152M	Hold	7,040,622	–	–	3.07%	7
2022 Q3	$141M	Hold	7,040,622	–	–	3.01%	5
2022 Q2	$126M	Buy	7,040,622 +980,532	+16%	+$10.1M	3.36%	5
2022 Q1	$60.1M	Buy	6,060,090 +1,094,502	+22%	+$14.5M	1.31%	22
2021 Q4	$83.7M	Hold	4,965,588	–	–	1.48%	18
2021 Q3	$118M	Hold	4,965,588	–	–	1.63%	21
2021 Q2	$113M	Buy	+4,965,588	New	+$104M	1.81%	14

Other funds holding DAWN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RA Capital Management's DAWN Position: Q2 2025 in Review

RA Capital Management sold out of Day One Biopharmaceuticals (DAWN) in Q2 2025, closing a stake of 5,755,577 shares — an estimated $45.6M sold.

RA Capital Management first reported a position in DAWN in Q2 2021 and held it in 16 quarters. The position peaked at $152M in Q4 2022. 174 funds tracked by Wall St. Rank hold DAWN as of Q2 2025.

RA Capital Management reported no remaining Day One Biopharmaceuticals position as of Q2 2025 after selling out during the quarter.
RA Capital Management sold 5,755,577 Day One Biopharmaceuticals shares in Q2 2025, an estimated $45.6M.
RA Capital Management first reported a position in Day One Biopharmaceuticals in Q2 2021 and held it in 16 quarters.
RA Capital Management's Day One Biopharmaceuticals position peaked at $152M in Q4 2022.
174 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2025.

Based on RA Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.